Mark D. Roycik

442 total citations
10 papers, 368 citations indexed

About

Mark D. Roycik is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Mark D. Roycik has authored 10 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cancer Research, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Mark D. Roycik's work include Protease and Inhibitor Mechanisms (7 papers), Peptidase Inhibition and Analysis (4 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Mark D. Roycik is often cited by papers focused on Protease and Inhibitor Mechanisms (7 papers), Peptidase Inhibition and Analysis (4 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Mark D. Roycik collaborates with scholars based in United States, China and Australia. Mark D. Roycik's co-authors include Qing‐Xiang Amy Sang, Paul A. Stewart, Jinfeng Zhang, Megan E. Muroski, Philippe E. Van den Steen, Howard M. Monroe, Ghislain Opdenakker, Xiao Fang, Jeremy S. Myers and Winston Tan and has published in prestigious journals such as PLoS ONE, Journal of Medicinal Chemistry and Cell Research.

In The Last Decade

Mark D. Roycik

10 papers receiving 360 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark D. Roycik United States	10	167	150	134	42	36	10	368
Zexuan Liu China	12	145 0.9×	197 1.3×	69 0.5×	30 0.7×	44 1.2×	25	378
Izabela Papiewska‐Pająk Poland	13	130 0.8×	224 1.5×	110 0.8×	49 1.2×	56 1.6×	24	408
Ian E. Anglin United States	10	93 0.6×	260 1.7×	86 0.6×	66 1.6×	48 1.3×	11	461
Suyu Miao China	8	210 1.3×	256 1.7×	99 0.7×	58 1.4×	41 1.1×	11	428
Mary A. Bewick Canada	13	80 0.5×	225 1.5×	157 1.2×	41 1.0×	39 1.1×	16	451
Roselyne Tournaire France	9	163 1.0×	292 1.9×	127 0.9×	44 1.0×	58 1.6×	11	458
J Grosfeld United States	5	149 0.9×	261 1.7×	122 0.9×	46 1.1×	30 0.8×	10	430
Alexander Hamm Germany	5	91 0.5×	209 1.4×	116 0.9×	44 1.0×	88 2.4×	9	385
María Villa‐Morales Spain	12	133 0.8×	274 1.8×	145 1.1×	39 0.9×	92 2.6×	23	452

Countries citing papers authored by Mark D. Roycik

Since Specialization

Citations

This map shows the geographic impact of Mark D. Roycik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Roycik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Roycik more than expected).

Fields of papers citing papers by Mark D. Roycik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Roycik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Roycik. The network helps show where Mark D. Roycik may publish in the future.

Co-authorship network of co-authors of Mark D. Roycik

This figure shows the co-authorship network connecting the top 25 collaborators of Mark D. Roycik. A scholar is included among the top collaborators of Mark D. Roycik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark D. Roycik. Mark D. Roycik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Bosco, Dale B., Mark D. Roycik, Yonghao Jin, et al.. (2017). A new synthetic matrix metalloproteinase inhibitor reduces human mesenchymal stem cell adipogenesis. PLoS ONE. 12(2). e0172925–e0172925. 16 indexed citations

Hoyne, Gerard F., Caroline Rudnicka, Qing‐Xiang Amy Sang, et al.. (2016). Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer. BMC Cancer. 16(1). 151–151. 13 indexed citations

Mu, Tianyang, Ying Ju, Mark D. Roycik, et al.. (2013). Efficient soluble expression of secreted matrix metalloproteinase 26 in Brevibacillus choshinensis. Protein Expression and Purification. 91(2). 125–133. 9 indexed citations

Xia, Wei‐Xiong, Yan‐Fang Ye, Xing Lü, et al.. (2013). The Impact of Baseline Serum C-Reactive Protein and C-Reactive Protein Kinetics on the Prognosis of Metastatic Nasopharyngeal Carcinoma Patients Treated with Palliative Chemotherapy. PLoS ONE. 8(10). e76958–e76958. 23 indexed citations

Roycik, Mark D., et al.. (2013). Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke. Current Molecular Medicine. 13(8). 1299–1313. 25 indexed citations

Stewart, Paul A., et al.. (2013). Differentially Expressed Transcripts and Dysregulated Signaling Pathways and Networks in African American Breast Cancer. PLoS ONE. 8(12). e82460–e82460. 77 indexed citations

Jin, Yonghao, Mark D. Roycik, Dale B. Bosco, et al.. (2013). Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core. Journal of Medicinal Chemistry. 56(11). 4357–4373. 15 indexed citations

Roycik, Mark D., et al.. (2009). A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates. Current Pharmaceutical Design. 15(12). 1295–1308. 40 indexed citations

Muroski, Megan E., et al.. (2008). Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis. Current Pharmaceutical Biotechnology. 9(1). 34–46. 110 indexed citations

10.

Iczkowski, Kenneth A., et al.. (2006). Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Research. 16(9). 750–758. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact